- Report
- March 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 134 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 129 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- February 2023
- 250 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- December 2024
- 85 Pages
India
From €3185EUR$3,500USD£2,731GBP
- Report
- December 2021
- 82 Pages
Asia Pacific
From €3640EUR$4,000USD£3,121GBP
- Report
- January 2022
- 110 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- March 2024
- 168 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Ritonavir is an antiretroviral drug used to treat HIV/AIDS. It is a protease inhibitor, meaning it blocks the action of the HIV protease enzyme, which is necessary for the virus to replicate. Ritonavir is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to treat hepatitis C virus (HCV) infection in combination with other antiviral drugs. Ritonavir is available in both oral and intravenous formulations.
Ritonavir is a widely used drug in the treatment of infectious diseases. It is used in combination with other antiretroviral drugs to treat HIV infection, and is also used to treat HCV infection in combination with other antiviral drugs. Ritonavir is also used to treat other viral infections, such as influenza and respiratory syncytial virus (RSV).
Some companies in the Ritonavir market include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Pfizer. Show Less Read more
